Breye Therapeutics Raises €67.5M for Oral Eye Drugs

Retinal disease treatment often becomes aggressive only after the condition has already progressed. Breye Therapeutics wants to challenge that pattern with oral medicines designed for earlier intervention. The Danish biotech has now raised €67.5 million to push that strategy deeper into clinical development.

The oversubscribed Series A will primarily support danegaptide, Breye Therapeutics’ lead drug candidate for non-proliferative diabetic retinopathy. The company plans to move the oral treatment into a randomized Phase 2 clinical trial. That study is expected to begin in 2027 and test whether the drug delivers meaningful clinical benefits.

The financing was co-led by Mission BioCapital and existing investor Novo Holdings. Sound Bioventures also returned, while several new investors joined the round. Those backers include EIFO, Innovestor Life Science, Catalyze Capital, Modi Ventures, Pappas Capital, and the Ljungström family office.

The size of the round reflects more than confidence in another experimental eye drug. Breye Therapeutics is pursuing a different treatment model for retinal disease. Instead of waiting until injections become necessary, it wants patients treated earlier with medicines they can take orally.

That approach could be especially important in diabetic retinopathy. The condition damages blood vessels in the retina and can eventually lead to serious vision loss. Current treatment options become more important as disease progresses, but earlier stages are often managed primarily through monitoring.

For Breye Therapeutics, that creates both a medical opportunity and a large commercial one. The company estimates diabetic retinopathy affects roughly 130 million people globally. It also believes the treatment market is already approaching $10 billion and could grow substantially over the coming decade.

Breye Therapeutics Wants Treatment to Start Before Vision Is Threatened

Treatment for diabetic retinopathy can include injections of anti-VEGF drugs directly into the eye. These medicines block vascular endothelial growth factor, which contributes to abnormal vessels and retinal leakage. Some patients initially need monthly injections before treatment intervals can gradually become longer.

Those therapies have transformed care for many patients with advanced disease. However, injecting medicine into the eye creates a treatment burden that oral medication could potentially reduce. Breye Therapeutics believes that difference could encourage treatment much earlier in the disease process.

The company’s lead candidate, danegaptide, is an oral small molecule designed to stabilize blood vessels inside the retina. Breye says it protects against capillary breakdown and vascular leakage caused by sustained high blood sugar. Its approach targets processes involved earlier in retinal damage.

That mechanism gives Breye Therapeutics a different position from therapies primarily targeting VEGF later in disease progression. The company describes danegaptide as working upstream of existing injected treatments. If successful, it could potentially complement those medicines rather than replacing every existing option.

There is already evidence explaining why researchers continue looking for earlier approaches. National Eye Institute guidance notes that early diabetic retinopathy is often monitored until treatment becomes more necessary. More advanced disease can then require injections, laser procedures, or other interventions.

Research has also shown that treating earlier does not automatically guarantee better vision outcomes. One NIH-backed study found preventive anti-VEGF injections reduced some disease complications. However, researchers initially found no meaningful vision advantage compared with beginning treatment later when complications developed.

That history raises the bar for Breye Therapeutics. An oral drug will need to offer more than convenience if it eventually reaches larger trials. Researchers must show that earlier treatment changes disease progression enough to provide meaningful long-term benefit.

Danegaptide has completed a Phase 1b trial involving patients with non-proliferative diabetic retinopathy and associated diabetic macular edema. The study examined safety, tolerability, drug exposure, and early biological activity. Breye reported that the treatment was well tolerated across evaluated dose levels.

The company also reported early imaging signals that suggested reduced retinal vascular leakage. More than half of participating patients showed imaging findings associated with lower leakage during the four-week treatment period. Researchers also observed reductions in some measurements of retinal swelling.

Those findings remain early and should not be treated as proof of clinical effectiveness. Phase 1 studies primarily establish safety and help researchers understand how a drug behaves. The planned Phase 2 trial will provide a more meaningful test of Breye Therapeutics’ central hypothesis.

A recent paper in Science Translational Medicine has added scientific support to that development program. The research examined preclinical evidence alongside early clinical findings involving danegaptide. Breye says the data support further investigation of the drug as an earlier, non-invasive treatment approach.

The upcoming Phase 2 study will focus on a targeted population with non-proliferative diabetic retinopathy. Breye plans to use improvement on the diabetic retinopathy severity scale as an important regulatory endpoint. Its current pipeline materials indicate clinical proof-of-concept data are expected in 2029.

Oral Retina Drugs Could Open a Much Larger Treatment Window

The larger opportunity for Breye Therapeutics extends beyond one diabetic retinopathy medicine. The company is building a pipeline around the idea that retinal diseases could benefit from easier oral treatments. That strategy includes programs addressing age-related macular degeneration and glaucoma.

One program targets the P2X7 receptor for intermediate age-related macular degeneration. Breye is developing oral inhibitors intended to reduce inflammation and nerve damage. Several molecules are moving toward studies needed before testing can begin in humans.

The company is also developing additional candidates for glaucoma with potential neuroprotective properties. Those programs remain earlier than danegaptide. However, they reinforce Breye Therapeutics’ broader plan to build oral medicines around diseases usually managed through specialized ophthalmic care.

That strategy could address a practical problem across retinal treatment. Eye injections can be highly effective, but patients must repeatedly return to clinics for procedures. Oral therapies may provide an easier path for treating much larger populations before serious complications develop.

Convenience alone will not guarantee adoption. Oral drugs can also create systemic side effects that locally delivered eye treatments may avoid. Breye Therapeutics will therefore need to demonstrate that its medicines remain safe during longer treatment periods.

Long-term adherence will matter as well. A tablet may appear easier than an injection, but patients still need strong reasons to continue medication consistently. Clinical benefits must be clear enough to justify chronic treatment during stages when symptoms may still be limited.

That makes the Phase 2 trial particularly important. It will test whether danegaptide can move beyond promising biological signals toward measurable disease improvement. Positive results could justify larger and more expensive late-stage clinical programs.

The €67.5 million financing gives Breye Therapeutics more resources to reach that point. It also gives the company enough capital to advance other assets while the lead program moves forward. That reduces some dependence on a single scientific idea.

Breye was founded in 2019 and remained relatively quiet before emerging publicly in 2022. Its early backing included Novo Holdings and Sound Bioventures. The latest round brings a broader group of specialist investors around the company.

New investors are also gaining representation at board level. Mission BioCapital partner Robert Blazej and Lukas Ljungström will join Breye’s board following the financing. Their involvement gives the company additional experience as it approaches more demanding clinical development stages.

The real test will still come from patients rather than investors. Danegaptide must show that taking treatment earlier produces outcomes strong enough to change clinical practice. That will require larger trials, longer follow-up, and convincing evidence of benefit.

If Breye Therapeutics succeeds, its biggest achievement may be changing when doctors begin treating retinal disease. Instead of waiting for disease progression before introducing burdensome procedures, physicians could eventually have an oral option earlier. That could create a much wider treatment window for diabetic retinopathy.

There is still considerable clinical risk before that idea becomes reality. Danegaptide has not yet completed the trials required for approval. Phase 2 will provide the next important indication of whether the concept can survive rigorous testing.

For now, the funding gives Breye Therapeutics enough momentum to find out. The company is no longer simply asking whether an oral retinal drug can work. It is preparing to test whether earlier treatment can meaningfully change how diabetic eye disease is managed.